新型α-CGRP类似物在实验性高血压、心肌肥厚和心力衰竭中保护终末器官
研究评估一种新型长效酰化α-CGRP类似物(半衰期≥7小时)在两种小鼠模型中对高血压和心力衰竭的心血管保护作用。在血管紧张素II诱导的高血压模型中,类似物减轻高血压并保护血管、肾脏和心脏功能;在腹主动脉缩窄模型中,类似物改善心脏功能并减轻不良重构。结果表明该类似物具有治疗心血管疾病的潜力。
要点
- αAnalogue(50 nmol·kg-1·d-1,皮下注射)减轻血管紧张素II诱导的高血压并保护终末器官。
- αAnalogue在腹主动脉缩窄模型中保留心脏功能并减轻不良重构和凋亡。
- αAnalogue治疗耐受良好,无脱敏或行为改变迹象。
核心结论
- 在两种不同小鼠模型中,稳定化αAnalogue通过抗高血压效应、减轻心脏重构以及增加血管生成和细胞存活,显示出治疗潜力。
研究设计与样本
- 研究在两种不同的小鼠高血压和心力衰竭模型中体内评估αAnalogue的效果。
- 血管紧张素II诱导的高血压模型观察14天,血压通过遥测术测量。
- 腹主动脉缩窄诱导的心肌肥厚和心力衰竭模型观察5周。
- 通过RNA分析、Western blot和组织学进行离体分析。
主要发现
- 在血管紧张素II诱导的高血压模型中,αAnalogue(50 nmol·kg-1·d-1,皮下注射)共治疗减轻高血压。
- αAnalogue保护血管、肾脏和心脏功能,表现为肥厚减轻以及纤维化、重构、炎症和氧化应激生物标志物减少。
- 在另一项研究中,αAnalogue逆转血管紧张素II诱导的高血压及相关血管和心脏损伤。
- 在腹主动脉缩窄模型中,αAnalogue治疗5周保留心脏功能(超声心动图评估)并减轻不良心脏重构和凋亡。
- αAnalogue治疗耐受良好,无脱敏或行为改变迹象。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Research into the therapeutic potential of α-calcitonin gene-related peptide (α-CGRP) has been limited because of its peptide nature and short half-life. Here, we evaluate whether a novel potent and long-lasting (t½ ≥7 hours) acylated α-CGRP analogue (αAnalogue) could alleviate and reverse cardiovascular disease in 2 distinct murine models of hypertension and heart failure in vivo. METHODS: The ability of the αAnalogue to act selectively via the CGRP pathway was shown in skin by using a CGRP receptor antagonist. The effect of the αAnalogue on angiotensin II-induced hypertension was investigated over 14 days. Blood pressure was measured by radiotelemetry. The ability of the αAnalogue to modulate heart failure was studied in an abdominal aortic constriction model of murine cardiac hypertrophy and heart failure over 5 weeks. Extensive ex vivo analysis was performed via RNA analysis, Western blot, and histology. RESULTS: The angiotensin II-induced hypertension was attenuated by cotreatment with the αAnalogue (50 nmol·kg-1·d-1, SC, at a dose selected for lack of long-term hypotensive effects at baseline). The αAnalogue protected against vascular, renal, and cardiac dysfunction, characterized by reduced hypertrophy and biomarkers of fibrosis, remodeling, inflammation, and oxidative stress. In a separate study, the αAnalogue reversed angiotensin II-induced hypertension and associated vascular and cardiac damage. The αAnalogue was effective over 5 weeks in a murine model of cardiac hypertrophy and heart failure. It preserved heart function, assessed by echocardiography, while protecting against adverse cardiac remodeling and apoptosis. Moreover, treatment with the αAnalogue was well tolerated with neither signs of desensitization nor behavioral changes. CONCLUSIONS: These findings, in 2 distinct models, provide the first evidence for the therapeutic potential of a stabilized αAnalogue, by mediating (1) antihypertensive effects, (2) attenuating cardiac remodeling, and (3) increasing angiogenesis and cell survival to protect against and limit damage associated with the progression of cardiovascular diseases. This indicates the therapeutic potential of the CGRP pathway and the possibility that this injectable CGRP analogue may be effective in cardiac disease.
引用
- Aubdool AA, Thakore P, Argunhan F, et al. A Novel α-Calcitonin Gene-Related Peptide Analogue Protects Against End-Organ Damage in Experimental Hypertension, Cardiac Hypertrophy, and Heart Failure. Circulation. 2017. PMID: 28446517. doi:10.1161/CIRCULATIONAHA.117.028388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。